Weekly Analysts’ Ratings Changes for Black Diamond Therapeutics (BDTX)

Several brokerages have updated their recommendations and price targets on shares of Black Diamond Therapeutics (NASDAQ: BDTX) in the last few weeks:

• 5/22/2026 – Black Diamond Therapeutics had its “outperform” rating reaffirmed by Raymond James Financial, Inc..
• 5/22/2026 – Black Diamond Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 5/22/2026 – Black Diamond Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 5/18/2026 – Black Diamond Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 5/9/2026 – Black Diamond Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/29/2026 – Black Diamond Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 4/29/2026 – Black Diamond Therapeutics had its price target raised by BTIG Research from $10.00 to $11.00. They now have a “buy” rating on the stock.
• 4/23/2026 – Black Diamond Therapeutics was upgraded by Jefferies Financial Group Inc. to “strong-buy”.
• 4/21/2026 – Black Diamond Therapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.